Recent

% | $
Quotes you view appear here for quick access.

Novavax, Inc. Message Board

rezoom2 673 posts  |  Last Activity: 3 hours ago Member since: Feb 11, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Why not Gilead?

    by jeddavid2 3 hours ago

    Do they have at least $6billion minimum to make an offer?

  • like Adam....?

  • rezoom2 rezoom2 May 24, 2015 3:47 PM Flag

    that's great timing for sure... topped by good strategy....

  • Reply to

    Kite Pharma

    by ltdobanion May 24, 2015 2:41 PM
    rezoom2 rezoom2 May 24, 2015 3:05 PM Flag

    they have 44.7 Million.... NVAX has Shares Outstanding 267.84M
    Their share price would be a comparative $6...more or less..

  • Reply to

    Kite Pharma

    by ltdobanion May 24, 2015 2:41 PM
    rezoom2 rezoom2 May 24, 2015 2:58 PM Flag

    lol... because they have maybe 66 shares outstanding... ?

  • rezoom2 rezoom2 May 24, 2015 1:38 PM Flag

    red... if you have the time... would you offer corrections on the 13 points? Which ones (these are from the web site, by the way) are false... and could they be better stated instead of eliminated?

    thanks/.

  • Reply to

    Vaccines developed for H5N1, H7N9 avian flu

    by tallpines25 May 24, 2015 11:09 AM
    rezoom2 rezoom2 May 24, 2015 11:53 AM Flag

    I have not read, thus far, of any humans developing bird flu in this latest round of flu in chickens and turkeys in the upper Midwest . Articles don't reveal information on the production of the bird vaccines, above. What are the commercial/economic ramifications in a vaccine for birds... poultry ?

  • •Simple and secure supply chain compared to egg-based production
    •Uses non-infectious, non-pathogenic organisms for humans, which removes the need for containment facilities
    •Suspension cell culture for easy scale-up
    •High-yielding cell culture system (compared to mammalian cell lines)
    •Reduces process and facility complexity compared to traditional approaches
    •Reduced capital equipment and facility costs
    •Reduced validation costs and time
    •Rapid expansion of capacity relative to traditional systems
    •Supports manufacturing with less labor
    •Fixed costs decreased
    •Smaller facilities feasible, supporting regional versus central supply
    •Single-use “closed” bioreactor manufacturing system preventing environmental product contamination
    •Insect cells do not support mammalian viruses; cell line qualification is streamlined

  • rezoom2 rezoom2 May 24, 2015 8:20 AM Flag

    Advantages specific to influenza:
    •Faster availability of product from new strains
    •Recombinant baculovirus production seed and reagents are available more quickly than influenza virus processes
    •High fidelity antigen match to wild-type (circulating) strains
    •Process supports selection of most cross-protective strain in vaccine formula; no need to compromise strain selection for productivity concerns
    •Low risk of microbial product contamination (sterility failures) relative to egg-based production.
    •Facilities easily adapted for multiple products when not making influenza

  • Matrix-M™ is Novavax' patented adjuvant for use in human vaccines and vaccines in certain animals. Matrix-M™ is the basis for all agreements and research collaborations in the human market.

    During 2009 a phase I study on avian flu was performed with Matrix-M™. The study fulfilled all predefined criteria with no serious adverse events. Matrix-M™ induces a cell-mediated and an antibody mediated immune response, which is expected to be important in future vaccines. In addition Matrix-M™ increases the opportunity for an immune reaction with longer duration, which can reduce the number of vaccinations needed to gain optimal protection. Another important advantage with Matrix-M™ is the good safety profile.

    Matrix-C™

    Matrix-C™ is used in vaccines for horses, including Intervets Equilis® Prequenza. Equilis® Prequenza was launched in 2006 the vaccine soon became a market leading vaccine against equine influenza. Novavax has produced millions of doses of Matrix- C™ for Equilis® Prequenza.

    Matrix-C™ is also used in the equine strangles vaccine under development in partnership with the Swedish company Intervacc. Strangles is a disease that creates large problems and the preliminary studies of the new strangles vaccine show promising data.

  • We believe our influenza virus-like particle (VLP) vaccine candidates have immunological advantages over current available vaccines. Our influenza VLPs contain three of the major structural virus proteins that are important for fighting influenza: hemagglutinin (HA) and neuraminidase (NA), both of which stimulate the body to produce antibodies that neutralize the influenza virus and prevent its spread through the cells in the respiratory tract, and matrix 1 (M1), which stimulates cytotoxic T lymphocytes to kill cells that may already be infected. Our VLPs are not made from live viruses and have no influenza genetic nucleic material in their inner core, which render them incapable of replicating and causing the disease.

    In recent years, trivalent influenza vaccines (three influenza strains: two influenza A strains and one influenza B strain) have been made generally available on a worldwide basis. With two distinct lineages of influenza B viruses circulating, governmental health authorities have advocated for the addition of a second influenza B strain to provide additional protection and it is expected that quadrivalent seasonal vaccines will ultimately replace trivalent seasonal vaccines in the global market.

    In November 2014, under our contract with HHS-BARDA, we initiated a Phase 2 clinical trial of our quadrivalent seasonal influenza VLP vaccine candidate in 400 healthy adults. The primary outcomes of the trial will assess safety and tolerability of the seasonal influenza VLP vaccine candidate and quantify immune responses to each of the four influenza strains based on hemagglutination-inhibiting antibody (HIA) titers. Secondary outcomes will evaluate neuraminidase-inhibition antibody titers for all four influenza strains.

  • rezoom2 rezoom2 May 23, 2015 4:23 PM Flag

    Monday will be a day to remember.

  • rezoom2 rezoom2 May 23, 2015 10:56 AM Flag

    perhaps you should... no one else will.

  • that the RSV vaccine antibodies are indeed carried over to the infant..
    to protect that infant for the first 3+ months of life...
    it will be deemed a landmark event.

    Couple that with the RSV/seasonal flu combo for elderly...another landmark event...
    And you have a company that will be sought by large pharmas which will pay heavily if they want to buy NVAX.

    If management can ward off the large pharma offers... the company will succeed with share prices in the high double digits...

    In any case... the future is very bright for long term share holders.

  • RSV vaccine... 3+ indications for the elderly...pregnant moms...children...with world wide market
    Flu vaccine, quad seasonal destined to dominate the flu vaccine market eventually
    Pandemic vaccines.. H5N1, H7N9, ebola
    Pipeline vaccines... Rabies (developing via CPLB partner in India) , MERS, SARS, malaria
    Platform of the future for vaccine development.. Virus-like-particle / recombinant technology.
    Various patents covering stages of vaccine development.
    NVAX owns Swedish developer (Isconova) of Matrix M (human) and Matrix C (for animals) adjuvants
    Management has extensive experience and proven ability.. (see resumes on web site)
    NVAX uses careful, step by step, rational development of vaccine products
    Treasury ... over $300 million and no debt
    Employee base now over 300 scientists and technologists... amazing growth in past 3 years.
    Funding by BARDA, PATH and expected Ebola vaccine funding post Australian ebola trial.
    19 vaccine trials successfully accomplished with 4 more due to be resolved in Q3-4
    Solid institutional ownership... (somewhere around 62-72% of shares)
    NVAX goal is to remain independent with marketing/production partners when and where needed.
    A stream of trial data in the coming 6 months.
    Initiation of phase III trials (RSV, quad seasonal flu) end of year and Q1, 2016

    To sum it up... Novavax is extremely stable, well funded and backed, with leading edge vaccines.

  • Reply to

    Give us a NINE! :-)

    by dallasjester888 May 20, 2015 3:03 PM
    rezoom2 rezoom2 May 20, 2015 4:44 PM Flag

    Nein !

  • rezoom2 rezoom2 May 20, 2015 12:29 PM Flag

    Good grief !! I overlooked our Matrix M, the adjuvant that made the Genocea herpes vaccine a potential success...

  • in the next 12 months... why?

    RSV vaccine... 3+ indications for the elderly...pregnant moms...children...with world wide market
    Flu vaccine, quad seasonal destined to dominate the flu vaccine market eventually
    Pandemic vaccines.. H5N1, H7N9, ebola
    Pipeline vaccines... Rabies, MERS, SARS, malaria
    Platform of the future for vaccine development
    Management with extensive experience and proven ability
    Strategy uses careful, step by step, rational development of the products
    Treasury ... over $300 million and no debt
    Funding by BARDA, PATH and expected Ebola vaccine funding post Australian ebola trial.
    19 vaccine trials successfully accomplished with 4 more due to be resolved in Q3-4
    Solid institutional ownership
    A vision and goal... to be a prominent, independent vaccine producer, with worldwide focus.

    In my own view... a double in the one year time frame is a conservative goal....

  • rezoom2 rezoom2 May 20, 2015 8:04 AM Flag

    In my uneducated view... any level of antibody production is better than none, vis-a-vis RSV and ebola. We won't know efficacy. With flu, there are competitive values to judge antibody levels, yet not efficacy yet. Previous trials of Novavax vaccines, considered successful, will be the objective comparatives, I would imagine. Your question is moot, and I believe flashfir is correct... just watch the share price and, as rpmanco says, take a gander at the big shareholders.. institutions...

  • Reply to

    GNCA Matrix M

    by jeddavid2 May 19, 2015 10:22 AM
    rezoom2 rezoom2 May 19, 2015 1:36 PM Flag

    testing with 3 strengths of MM is a strong sign as to its significance.

NVAX
8.87+0.01(+0.11%)May 22 4:00 PMEDT